NEW YORK (GenomeWeb) – The US Preventative Services Task Force today updated its cervical cancer screening recommendations to advise that women aged 30 to 65 may choose to get screened every three years with cervical cytology alone, every five years with high-risk HPV testing alone, or every five years with hrHPV testing in combination with cytology, also known as cotesting.
The task force also recommends that women aged 21 to 29 should get screened every three years with cervical cytology alone, also known as a Pap smear. USPSTF recommends against screening women over age 65 who have had adequate prior screening and are not otherwise at high risk for cervical cancer, or women who have had a hysterectomy with removal of the cervix and do not have a history of high-grade precancerous lesion or cervical cancer.
The recommendations represent a change from prior ones in that it introduces hrHPV testing alone as a new recommendation. According to the USPSTF, for women aged 30 to 65 cytology alone every three years or hrHPV testing every five years are the “preferred screening strategies based on USPSTF review of trial, cohort, and modeling results.” The task force’s 2012 recommendations advised cytology alone every